CAR T cell therapy targets key mutation driving rare blood cancers

A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group ...
News-Medical.Net

First-in-class experimental CAR T-cell therapy shows promise against solid tumors

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

AI framework helps identify new targets for CAR T cell therapy

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers ...

CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...
Health and Me on MSN

How CAR-T cell therapy is transforming blood cancer treatment

CAR-T therapy is a highly specialized treatment that requires careful patient selection and close monitoring. Some patients ...
The American Journal of Managed Care

Flow Cytometry Tracks CAR T-Cell Therapy Persistence in Aggressive LBCL

Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...
The American Journal of Managed Care

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Target selection leverages DLL3’s high tumor-surface expression in SCLC/LCNEC and limited normal-tissue expression, while dnTGFBR2 “armoring” aims to blunt TGF-β–mediated T-cell suppression. Dose ...
Fred Hutch

Understanding Parkinsonism after CAR T therapy

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...